Amundi
RARE icon

Amundi’s Ultragenyx Pharmaceutical RARE Stock Holding History

Amundi’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Buy
+15,166
New +$342K ﹤0.01% 1723
2025
Q4 		– Sell
-99,161
Closed -$2.99M – 1885
2025
Q3 		$2.99M Hold
99,161
– – ﹤0.01% 1014
2025
Q2 		$3.91M Buy
99,161
+93,189
+1,560% +$3.36M ﹤0.01% 965
2025
Q1 		$210K Hold
5,972
– – ﹤0.01% 1668
2024
Q4 		$261K Hold
5,972
– – ﹤0.01% 1685
2024
Q3 		$318K Buy
5,972
+2,034
+52% +$104K ﹤0.01% 1536
2024
Q2 		$158K Sell
3,938
-15,712
-80% -$671K ﹤0.01% 1623
2024
Q1 		$852K Sell
19,650
-75,288
-79% -$3.55M ﹤0.01% 1316
2023
Q4 		$4.59M Sell
94,938
-33,054
-26% -$1.28M ﹤0.01% 1001
2023
Q3 		$4.3M Hold
127,992
– – ﹤0.01% 1015
2023
Q2 		$5.97M Buy
127,992
+90,062
+237% +$4.18M ﹤0.01% 946
2023
Q1 		$1.47M Sell
37,930
-714
-2% -$30.6K ﹤0.01% 1202
2022
Q4 		$1.61M Buy
38,644
+32,286
+508% +$1.27M ﹤0.01% 1234
2022
Q3 		$258K Buy
+6,358
New +$327K ﹤0.01% 1429

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Amundi's RARE Position: Q1 2026 in Review

Amundi opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 15,166 shares worth $318K. The stake represents ﹤0.01% of the portfolio and ranks #1723 among its holdings. This is a return to the name: Amundi previously reported a position in RARE as recently as Q3 2025.

Amundi first reported a position in RARE in Q3 2022 and has held it in 14 quarters since. The position peaked at $5.97M in Q2 2023. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Amundi held 15,166 shares of Ultragenyx Pharmaceutical worth $318K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Amundi position in Q1 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1723 holding.
  • Amundi first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and has held it in 14 quarters since.
  • Amundi's Ultragenyx Pharmaceutical position peaked at $5.97M in Q2 2023.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.